IDEAYA Biosciences, Inc. (IDYA) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Company performance

Add to research

Current Price

as of Mar 21, 2025

$18.39

P/E Ratio

N/A

Market Cap

$1.61B

Description

Add to research

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Metrics

Add to research

Overview

HQSouth San Francisco, CA
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerIDYA
Price$18.39-0.27%

Trading Information

Market cap$1.61B
Float92.35%
Average Daily Volume (1m)913,459
Average Daily Volume (3m)893,328
EPS-$3.36

Company

Revenue$7.00M
Rev growth (1yr)-70.07%
Net income-$274.48M
Gross margin45.23%
EBITDA margin-4,616.30%
EBITDA-$323.14M

EV$1.44B
EV/Revenue206.00
P/EN/A
P/S214.58
P/B1.50
Debt/Equity1.81

Documents

Add to research

Earnings Calls

Earnings Report 2021Q4

Earnings Report (2022-03-15)

Factset

Factset Business Description

Factset Street Account

IDEAYA Biosciences reports Q3 EPS ($0.46) vs FactSet ($0.49) [11 est, ($0.77)-(0.25)] ($28.93, 0.00) (2023-11-07T11:07:51Z)

IDEAYA Biosciences reports preliminary cash, cash equivalents and marketable securities of $511.1M as of 30-Sep-23; provides update on ATM facility with Jefferies - 8-K ($27.25, 0.00) (2023-10-24T20:31:58Z)

IDEAYA Biosciences announces proffered paper oral presentation at ESMO 2023 for Phase 2 clinical data update for darovasertib and crizotinib combination in metastatic uveal melanoma ($24.59, 0.00) (2023-10-17T10:04:40Z)

IDEAYA Biosciences announces pricing of $125.0M common stock and pre-funded warrants through JPMorgan, Goldman Sachs, Jefferies, and RBC Capital Markets ($27.25, 0.00) (2023-10-25T02:48:19Z)

IDEAYA Biosciences announces development candidate nomination of Werner Helicase Inhibitor in collaboration with GSK ($26.67, 0.00) (2023-10-09T10:02:29Z)

IDEAYA announces top-line Phase 2 results at ESMO 2023 of darovasertib and crizotinib combo in MUM, and clinical efficacy updates for Neoadjuvant UM, GNAQ/11 cutaneous melanoma, and synthetic lethality pipeline ($25.29, 0.00) (2023-10-23T10:08:37Z)